Document is current

Article History

Received: 24 October 2022

Accepted: 5 September 2023

First Online: 18 September 2023

Declarations

:

: The chart review was conducted according to the Market Research Society Code of Conduct 2014. This code of conduct does not require any regulatory or ethics approvals. No experiments on humans were conducted, and there was no use of human tissue samples, therefore no patient or legal guardian consent was required. All requisite permissions for each physician to participate in the study were obtained from their respective hospitals. All physicians provided their informed consent to participate in this study. PRFs were filled out by physicians for each patient without any direct contact with patients or any primary data collection from patients, and all information was anonymised. Data protection laws were adhered to throughout the study (EU 2016/679 General Data Protection Regulation), and international codes of conduct were also followed in each country involved in the study.

: Not applicable.

: JT has received honoraria for speaker or advisory role from Amgen, Astellas, BMS, Merck-Serono, MSD, Novartis, Pierre Fabre, Roche and Servier.TS has received honoraria from Amgen, Bayer, Merck, Sanofi, Celgene, Shire, Roche, Falk Foundation, and AstraZeneca. He has served on advisory boards for Lilly, Amgen, Bayer, Celgene, Merck-Serono, Servier, AstraZeneca, Pierre Fabre, Cantargia, Scandion Oncology and has received research support from Boehringer Ingelheim, Sanofi and BMS.MR has received grants or contracts from Celgene and Astra Zeneca and has participated in Data Safety Monitoring Boards or advisory boards for Panavance, Viatris, SOTIO, Servier, MSD, Astra Zeneca, and Celgene.DP has received grants or contracts from BMS, Bayer, Sirtex and Nucana. He has received honoraria from Sirtex and Vitaris. He has participation in Data Safety Monitoring Boards or advisory boards for Boston Scientific, Eisai and AstraZeneca.JB has received consulting fees from Roche, Taiho, Incyte, and Servier. He has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Incyte.AC has no conflicts of interest to declare.GP has received consulting fees and honoraria from Merck Serono, Roche, Amgen, Sanofi, Lilly, Servier, Taiho, Bayer, Halozyme, BMS, MSD, Celgene, Pierre Fabre, Shire, and Terumo. He has had a leadership or fiduciary role in other board, society, committee, or advocacy group paid or unpaid for ESMO and CECOG.AV, FHB and ZT are employees of Servier.TM has served in a consultancy/advisory role with Amgen, Baxter, Celgene, Incyte, Q&D Therapeutics, Servier, Shire, AstraZeneca, and received research funding from AstraZeneca, BeiGene, Celgene.